A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma
← catalyst calendarNCT06381141 · readout ≤ 42 d
Sponsored by Cullinan Therapeutics Inc. (industry) · CGEM — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
30estimated
Sites
8
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-09-03 | actual | When the study began enrolling |
| Primary completion | Sep 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2024-04-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Multiple Myeloma
Intervention
- Drug: CLN-619
Primary outcomes
what the primary-completion date above is the date OFProportion of participants reporting Adverse Events (AEs) and Serious Adverse Events (SAEs)
measured baseline through 3-week treatment period
Changes in Eastern Cooperative Oncology Group (ECOG) performance
measured Up to 2 years
Incidence of Dose-Limiting toxicity (DLTs)
measured up to 2 years
Best Overall Response (BOR) per patient
measured up to 2 years
Overall Response Rate (ORR)
measured up to 2 years
Duration of Response (DoR)
measured up to 2 years
Clinical Benefit Rate (CBR)
measured up to 2 years
Progression Free Survival (PFS)
measured up to 2 years
Overall Survival (OS)
measured up to 2 years
Permalink · CGEM's whole pipeline · Catalyst calendar · Every registered study · What changed